Moleculin Biotech, Inc. (NASDAQ:MBRX) will release its earnings data on Monday, November 20th.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.19) EPS for the quarter.

Moleculin Biotech, Inc. (NASDAQ:MBRX) opened at $1.62 on Monday. Moleculin Biotech, Inc. has a 12-month low of $0.71 and a 12-month high of $3.75.

Separately, ValuEngine upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

ILLEGAL ACTIVITY NOTICE: “Moleculin Biotech, Inc. (MBRX) Set to Announce Earnings on Monday” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/12/moleculin-biotech-inc-mbrx-set-to-announce-earnings-on-monday.html.

In other Moleculin Biotech news, major shareholder Waldemar Priebe sold 100,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $1.70, for a total value of $170,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.80% of the stock is owned by insiders.

An institutional investor recently raised its position in Moleculin Biotech stock. Vanguard Group Inc. lifted its stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) by 27.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 337,321 shares of the company’s stock after purchasing an additional 73,161 shares during the period. Vanguard Group Inc. owned approximately 1.90% of Moleculin Biotech worth $631,000 at the end of the most recent reporting period. Institutional investors own 5.08% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Receive News & Ratings for Moleculin Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.